30 results about "Factor D" patented technology

The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.

The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.

The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and / or complement-associated disorders.

The invention provides anti-Factor D antibodies and conjugates and methods of using the same.

The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and / or predictive biomarkers.

A method for the diagnosis of C3NeF-mediated membranoproliferative glomerulonephritis (MPGN) in a sample comprising: a) immobilization of C3b in at least two wells of a plate; b) formation in said wells of the C3bBb complex, and, optionally, denaturation of the same complex, optionally with the addition of Factor H (FH), wherein said formation of the complex is mediated by the addition of IgGs purified from said sample and / or control in the presence of Factor B (FB), Factor D (FD), bovine serum albumin (BSA), magnesium ions; d) detachment of the formed complexes; e) electrophoretic run under denaturing conditions of said complexes and transfer on a membrane; detection of the protein of interest, Bb, which is one of the two components of C3 convertase; wherein the ratio of the intensities measured for the Bb band in the samples collected by each of said wells is indicative of C3NeF activity in said sample.

The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.

A kind of natural cell growth regulating factor D and its preparation method, it is first to screen Gram-positive, negative cocci or bacilli and freeze the strains, culture the strains routinely at 4-38°C, and filter at least once Extract the natural gene after removing the harmful bacteria, quantitatively add isoleucine amino acid to the natural gene, and seal it under the GMP standard after safety testing. 1 μg of the natural gene in the natural cell growth regulator D can be configured There are more than 1 μg of isoleucine amino acid, which can better promote the activation of the body and enhance immune function, can promote the proliferation and proliferation of capillaries at fracture ends and diseased parts, and promote the repair and remodeling of diseased tissue cells.